P. Pacheco

Discovery of (S)-1-(1-(4-Chloro-3-fluorophenyl)-2-hydroxyethyl)-4-(2-((1-methyl-1H-pyrazol-5-yl)amino)pyrimidin-4-yl)pyridin-2(1H)-one (GDC-0994), an Extracellular Signal-Regulated Kinase 1/2 (ERK1/2) Inhibitor in Early Clinical Development.

Dolores Diaz, Jianping Yin, Michael Burkard, 2016, Journal of medicinal chemistry.

Discovery of highly potent, selective, and efficacious small molecule inhibitors of ERK1/2.

J. Blake, Jianping Yin, Weiru Wang, 2015, Journal of medicinal chemistry.

Pharmacokinetic–Pharmacodynamic Analysis of Vismodegib in Preclinical Models of Mutational and Ligand-Dependent Hedgehog Pathway Activation

T. Januario, F. D. de Sauvage, R. Yauch, 2011, Clinical Cancer Research.

A Selective PIM Kinase Inhibitor Is Highly Active In Multiple Myeloma: The Biology of Single Agent and PI3K/AKT/mTOR Combination Activity

A. Ebens, L. Friedman, H. Maecker, 2010 .

A Selective PIM Kinase Inhibitor Is Highly Active In Multiple Myeloma: Mechanism of Action and Signal Transduction Studies

A. Ebens, L. Friedman, H. Maecker, 2010 .

Discovery of 5,6,7,8-tetrahydropyrido[3,4-d]pyrimidine inhibitors of Erk2.

J. Blake, Jianping Yin, Weiru Wang, 2014, Bioorganic & medicinal chemistry letters.

Abstract DDT02-03: Discovery of GDC-0994, a potent and selective ERK1/2 inhibitor in early clinical development

S. Gould, M. Belvin, Peter Yin, 2014 .

Pharmacokinetic–Pharmacodynamic Analysis of Vismodegib in Preclinical Models of Mutational and Ligand-Dependent Hedgehog Pathway Activation

T. Januario, F. D. de Sauvage, R. Yauch, 2011, Clinical Cancer Research.